A 42-year-old man from rural Maharashtra presents with a 6-month history of progressive abdominal distension and early satiety. Imaging reveals a large retroperitoneal mass with areas of necrosis and hemorrhage. Biopsy shows a high-grade spindle cell sarcoma. Genetic analysis identifies a heterozygous germline mutation in the TP53 gene (exon 7, missense mutation). The tumor shows loss of the wild-type TP53 allele on fluorescence in situ hybridization (FISH). Which of the following best explains why this patient developed a sarcoma at a relatively young age, and why the tumor is aggressive?

Explanation

## Li-Fraumeni Syndrome and TP53 Inactivation ### Clinical Context: Germline TP53 Mutation **Key Point:** This patient has Li-Fraumeni syndrome (LFS), a hereditary cancer predisposition syndrome caused by germline TP53 mutations. Affected individuals carry one mutant TP53 allele in every cell and have a dramatically elevated lifetime cancer risk (>90% by age 70). ### The Two-Hit Model in TP53-Associated Tumors **High-Yield:** TP53 is the "guardian of the genome." In normal cells, p53: 1. Detects DNA damage via ATM/ATR kinases 2. Halts cell-cycle progression at G1/S checkpoint (via p21 induction) 3. Activates apoptosis if damage is irreparable (via BAX, PUMA induction) 4. Suppresses angiogenesis and metastasis In this patient: - **Hit 1 (germline):** Inherited mutant TP53 allele → impaired p53 function in all cells - **Hit 2 (somatic):** Loss of the remaining wild-type allele in the sarcoma cell → complete loss of p53-mediated tumor suppression **Clinical Pearl:** The FISH result showing loss of the wild-type allele is the critical evidence of the second hit. Without both alleles inactivated, p53 retains some protective function. ### Why Early Onset and Aggressive Behavior? | Feature | Mechanism | |---------|----------| | Early age of onset (42 years) | Every cell starts with one defective TP53 allele; only one somatic event needed for complete loss | | High-grade, aggressive tumor | Loss of p53 → uncontrolled cell proliferation, evasion of apoptosis, genomic instability | | Sarcoma (not carcinoma) | TP53 mutations predispose to mesenchymal malignancies (sarcomas, osteosarcomas, brain tumors) | | Necrosis and hemorrhage | Rapid, uncontrolled growth outpaces blood supply | ### Contrast: Sporadic vs. Hereditary TP53 Loss **Mnemonic:** **LFS = Loss of Function + Loss of allele = Loss of all checkpoints** - **Sporadic cancer:** Two independent somatic hits required in the same cell (rare event, late onset) - **LFS:** One germline hit + one somatic hit (common event, early onset, multiple cancers) ### Why Not Gain-of-Function? Most germline TP53 mutations in LFS are loss-of-function (deletions, frameshifts, nonsense mutations). Even missense mutations typically impair p53's DNA-binding domain or transactivation domain, reducing—not enhancing—its tumor-suppressive function. Gain-of-function TP53 mutations occur in some somatic tumors but are rare in germline LFS. [cite:Robbins 10e Ch 7]